<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422888</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10048</org_study_id>
    <secondary_id>2014-005363-33</secondary_id>
    <nct_id>NCT02422888</nct_id>
  </id_info>
  <brief_title>Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor</brief_title>
  <acronym>REDUCE-MVI</acronym>
  <official_title>Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial will compare the protective effect of ticagrelor and prasugrel on
      microvascular dysfunction in patients with revascularized ST elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary microvascular dysfunction is highly prevalent in revascularized ST-elevation
      myocardial infarction and has important prognostic implications. Current data suggest that
      ticagrelor might be superior to prasugrel in the reduction of coronary microvasculature
      dysfunction. Thus, we have designed a clinical trial that will compare microvascular function
      in revascularized ST-elevation myocardial infarction patients at treatment steady state with
      ticagrelor or prasugrel. Coronary microvascular dysfunction will be assessed with the index
      of microcirculatory resistance after primary percutaneous coronary intervention and at 1
      month follow-up in the infarct-related vessel and non-infarct related vessel.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microcirculatory resistance (IMR)</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured in the infarct-related artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta Index of microcirculatory resistance (IMR)</measure>
    <time_frame>Baseline vs. 1 month follow-up</time_frame>
    <description>measured in the infarct-related artery and non-infarct related artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reactive hyperemia index (RHI)</measure>
    <time_frame>1 month and 1 year after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) recovery</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction</measure>
    <time_frame>3 days after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymmetric Dimethylarginine (ADMA) levels</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>Blood measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-myocardial haemorrhage</measure>
    <time_frame>3 days after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent

          2. Patients presenting with ST-elevation myocardial infarction &lt;12 hours after symptom
             onset

          3. Successful percutaneous coronary intervention of the infarct-related vessel with a
             modern drug-eluting stent

          4. Intermediate stenosis in non-infarct-related vessel (50-90%)

        Exclusion Criteria:

          1. history of myocardial infarction

          2. Participation in another clinical study with an investigational product during the
             preceding 30 days

          3. history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA)

          4. History of intracranial haemorrhage

          5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol)

          6. severe liver dysfunction (Child-Pugh score 10-15)

          7. congestive heart failure

          8. cardiogenic shock

          9. left ventricular ejection fraction &lt; 35%

         10. bleeding diathesis

         11. age â‰¥ 75 or &lt; 18

         12. body weight &lt; 60 kg

         13. gout

         14. coagulation disorders

         15. severe pulmonary disease

         16. pregnancy and breast feeding

         17. limited life expectancy

         18. platelet count &lt; 100 000/mm3

         19. history of drug addiction or alcohol abuse in the past 2 years

         20. need for chronic nonsteroidal anti-inflammatory drug

         21. creatinine clearance &lt;30 mL/min or dialysis

         22. chronic total occlusion (CTO)

         23. Left main disease

         24. allergy or contra-indication for ticagrelor or prasugrel

         25. Contra-indication for adenosine

         26. Patients unable to be followed on-site

         27. Unable to undergo or contra-indications for MRI

         28. Contra-indication for drug-eluting stent

         29. Inability to obtain informed consent

         30. Coronary artery bypass grafting in medical history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Maarten van Leeuwen</investigator_full_name>
    <investigator_title>Study coordinator</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

